CharlesStewartFuchsMD

Gastrointestinal Cancer, Hematologic Oncology

Director, Yale Cancer Center Physician-in-Chief, Smilow Cancer Hospital Richard and Jonathan Sackler Professor of Internal Medicine, Yale School of Medicine

Join to view full profile

Dr. Fuchs is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fuchs' full profile

Already have an account?

Office
333 Cedar St
Yale Cancer Center
New Haven, CT 06510
Phone+1 203-785-7870

Fax+1 203-785-4116

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1989 - 1992
Brigham and Women's HospitalResidency, Internal Medicine, 1986 - 1989
Harvard Medical SchoolClass of 1986

Certifications & Licensure

CT State Medical License 2016 - 2025
MA State Medical License 1988 - 2025
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Boston Magazine Castle Connolly, 2008, 2010-2013

Clinical Trials

Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Start of enrollment: 1998 Oct 01
Completed
Phase 3
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer Start of enrollment: 2001 Nov 01
Completed
Phase 1
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Start of enrollment: 2002 Dec 01
Completed
Phase 3
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma Start of enrollment: 2001 Nov 01
Completed
Phase 2
Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma Start of enrollment: 2000 Sep 01
Completed
Early Phase 1
Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer Start of enrollment: 1998 Jan 01
Completed
Phase 1
Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies Start of enrollment: 1999 Sep 01
Completed
Phase 1
RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer Start of enrollment: 2007 Jan 01
Completed
Phase 2
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer Start of enrollment: 2007 Oct 01
Completed
Phase 1, Phase 2
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
Completed
Phase 1
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Start of enrollment: 2015 Jul 29
Completed
Phase 1
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer Start of enrollment: 2015 Oct 12
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

40 citations
A comprehensive survey of genetic variation in 20,691 subjects from four large cohorts.
Sara Lindström, Stephanie Loomis, Constance Turman, Hongyan Huang, Jinyan Huang
Plos One. 2017-03-16
67 citations
Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer.
Yoshifumi Baba, Katsuhiko Nosho, Kaori Shima, Jeffrey A. Meyerhardt, Andrew T. Chan
British Journal of Cancer. 2010-09-28
252 citations
PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
Shuji Ogino, Katsuhiko Nosho, Gregory J. Kirkner, Kaori Shima, Natsumi Irahara
Journal of Clinical Oncology. 2009-03-20

Journal Articles

Germline Cancer Susceptibility Gene Variants, Somatic Second Hits, and Survival Outcomes in Patients with Resected Pancreatic Cancer
Richard F Dunne, Leona A Doyle, William C Hahn, Jason L Hornick, Andrea J Bullock, Sapna Syngal, Albert C Koong, Natalia Khalaf, Brian M Wolpin, Douglas A Rubinson, Da..., Nature

Lectures

A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (G...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Lifestyle Factors & Cancer Survival Prediction ModelsFebruary 28th, 2022
A Book Draws on 50 Years of Accumulated Wisdom, Calls for “A New Deal for Cancer”December 10th, 2021
Yale Cancer Center Experts Co-Author Book on War on CancerNovember 16th, 2021
Join now to see all

Grant Support

A Prospective Study Of Diet And Colorectal NeoplasiaNational Cancer Institute2010–2011
Prospective Cohort Collaborative In Pancreatic Cancer Epidemiology &PathogenesisNational Cancer Institute2007–2011
Dietary And Lifestyle Determinants Of Colon Cancer Recurrence And SurvivalNational Cancer Institute2007–2011
Df/Hcc Spore In Gastrointestinal CancerNational Cancer Institute2007–2011
Defining Optimal Doses Of Vitamin D For Chemoprevention In African AmericansNational Cancer Institute2007–2011
A Prospective Study Of Diet And Colorectal NeoplasiaNational Cancer Institute2007–2009
Administration, Evaluation, And PlanningNational Cancer Institute2007
Prospective Study Of Pancreatic Cancer PathogenesisNational Cancer Institute2000–2004
Prospective Study Of Diet And Colorectal NeoplasiaNational Cancer Institute2001–2002
Family History And The Risk Of Common MalignanciesNational Cancer Institute1995–1999